These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
447 related articles for article (PubMed ID: 8713691)
1. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Webster J Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691 [TBL] [Abstract][Full Text] [Related]
2. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Rains CP; Bryson HM; Fitton A Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332 [TBL] [Abstract][Full Text] [Related]
5. Cabergoline: a new drug for the treatment of hyperprolactinaemia. Ferrari C; Piscitelli G; Crosignani PG Hum Reprod; 1995 Jul; 10(7):1647-52. PubMed ID: 8582955 [TBL] [Abstract][Full Text] [Related]
6. Dopamine receptor agonists for treating prolactinomas. Colao A; di Sarno A; Pivonello R; di Somma C; Lombardi G Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422 [TBL] [Abstract][Full Text] [Related]
7. [Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study]. Pascal-Vigneron V; Weryha G; Bosc M; Leclere J Presse Med; 1995 Apr; 24(16):753-7. PubMed ID: 7784413 [TBL] [Abstract][Full Text] [Related]
8. Cabergoline and hyperprolactinaemia: new preparation. Better than bromocriptine. Prescrire Int; 2000 Feb; 9(45):195-7. PubMed ID: 11503793 [TBL] [Abstract][Full Text] [Related]
9. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Sabuncu T; Arikan E; Tasan E; Hatemi H Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944 [TBL] [Abstract][Full Text] [Related]
11. Diagnosis and drug therapy of prolactinoma. Ciccarelli E; Camanni F Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617 [TBL] [Abstract][Full Text] [Related]
16. Hyperprolactinemia: pathophysiology and management. Verhelst J; Abs R Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552 [TBL] [Abstract][Full Text] [Related]
17. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175 [TBL] [Abstract][Full Text] [Related]
18. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. Webster J; Piscitelli G; Polli A; Ferrari CI; Ismail I; Scanlon MF N Engl J Med; 1994 Oct; 331(14):904-9. PubMed ID: 7915824 [TBL] [Abstract][Full Text] [Related]
19. New drugs for hyperprolactinaemia. Drug Ther Bull; 1995 Sep; 33(9):65-7. PubMed ID: 7588002 [TBL] [Abstract][Full Text] [Related]
20. Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. European Multicentre Study Group for Cabergoline in Lactation Inhibition. BMJ; 1991 Jun; 302(6789):1367-71. PubMed ID: 1676318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]